Press Releases
Filter by:
Lantheus Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging
Cerveau Technologies, Inc, is now a subsidiary of Lantheus
Cerveau Technologies Inc. and Prothena Sign Agreement to Provide Novel Tau Imaging Biomarker for Research and Development of Investigational Therapeutics for Neurodegenerative Diseases
C-Path and Cerveau Technologies, Inc. Announce Data Sharing Collaboration to Accelerate Drug Development for Alzheimer’s Disease and Related Dementias
Cerveau Technologies Inc. and Alnylam® Pharmaceuticals Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier Research
Cerveau Technologies, Inc. Announces Collaboration with University College of London
Cerveau Technologies, Inc. Announces Collaboration with Alector, Inc.
Cerveau Technologies, Inc. Announces Initiation of Japanese Phase I Study
Cerveau Technologies Inc. Signs Research Agreement with Takeda to Provide Novel Tau Imaging Agent
Cerveau Technologies, Inc. Announces a Partnership with LuMind IDSC Foundation to Study Accumulation of Neurofibrillary Tau in Down Syndrome
This product candidate is an investigational drug that has not yet been approved as safe and effective.